Carer burden and behavioral disturbance is similar between younger-onset Alzheimer's disease and behavioral variant frontotemporal dementia

Matthew JY Kang; Sarah Farrand; Andrew Evans; Wei-Hsuan Chiu; Dhamidhu Eratne; Wendy Kelso; Mark Walterfang; Dennis Velakoulis; Samantha M Loi

Journal article

Carer burden and behavioral disturbance is similar between younger-onset Alzheimer's disease and behavioral variant frontotemporal dementia

Matthew JY Kang, Sarah Farrand, Andrew Evans, Wei-Hsuan Chiu, Dhamidhu Eratne, Wendy Kelso, Mark Walterfang, Dennis Velakoulis, Samantha M Loi

International Psychogeriatrics | Cambridge University Press | Published : 2024

DOI: 10.1017/S1041610222001259

Download PDF

Abstract

Objectives: Carer burden is common in younger-onset dementia (YOD), often due to the difficulty of navigating services often designed for older people with dementia. Compared to Alzheimer's disease (AD), the burden is reported to be higher in behavioral variant frontotemporal dementia (bvFTD). However, there is little literature comparing carer burden specifically in YOD. This study hypothesized that carer burden in bvFTD would be higher than in AD. Design: Retrospective cross-sectional study. Setting: Tertiary neuropsychiatry service in Victoria, Australia. Participants: Patient-carer dyads with YOD. Measurements: We collected patient data, including behaviors using the Cambridge Behavioral..

View full abstract

University of Melbourne Researchers

Matthew Kang Author

Andrew Evans Author

Dhamidhu Eratne Author

Mark Walterfang Author

Grants

Funding Acknowledgements

AHE reports honoraria for presentations from Merck, Allergan, Ipsen, Teva, UCB, Abbott, AbbVie, STADA. Participation in scientific advisory board meetings with Allergan, Ipsen AbbVie, and STADA. He holds shares in GKC and CSL. MW reports honoraria for presentations from Biomarin, Actelion, Vtesse, Shire, Orphan, and Mallinkrodt; participation in scientific advisory board meetings with Biomarin, Actelion, Vtesse, Mallinkrodt and Orphazyme, and funding for research from Actelion, Pfizer, Lilly, and Bristol-Meyers-Squibb. DV reports participation in scientific advisory board meetings with Roche, Teva and funding for research from Actelion. SF reports a fellowship with Medtronic in 2016 and honoraria from AbbVie in 2020. SML reports funding from the NHMRC Early Career Fellowship and Yulgilbar Alzheimer's Research Program and honoraria for presentations from Otsuka and Lundbeck. DE reports funding from an NHMRC Ideas Grant.